tirzepatide vs semaglutide safety profile Subcutaneously administered for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials | Diabetologia Comparative safety and side effects
Description
The most commonly reported issues are gastrointestinal, including nausea, diarrhea, vomiting, constipation, and stomach pain
We go deeper into how hormones such as DHT govern hair loss in our article on hormones and hair
Tirzepatide lowered A1C by up to 2.46% in trials, outperforming other GLP-1 medications on glycemic control
Im already seeing results
Discuss with a qualified healthcare provider
For clarity, only the losses obtained for the highest dose of tirzepatide (15 mg) are shown in the figure
